article thumbnail

STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug

STAT

But Public Citizen maintains Medicare officials should consider the ongoing cost of the patenting tactics when negotiating a price. Here’s the backstory: Enbrel was the centerpiece of a 2002 deal in which Amgen acquired another company called Immunex that had developed the medicine.

article thumbnail

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. 6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002.

article thumbnail

ASBM’s Comments on the Medicare Drug Price Negotiation Plan: Protecting Patients and Ensuring Access to Medicines

Safe Biologics

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. First, the policy itself has built-in-problems. 2 Furthermore, cancer death rates per 100,000 are 1.6

article thumbnail

ASBM’s Comments on the Medicare Drug Price Negotiation Plan: Protecting Patients and Ensuring Access to Medicines

Safe Biologics

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. First, the policy itself has built-in-problems. 2 Furthermore, cancer death rates per 100,000 are 1.6

article thumbnail

What is the solution to America’s deepening access to medicines crisis?

pharmaphorum

But are price caps the best way to secure access to medicines, or does America have a more systemic problem? Democrat Joe Biden was elected partly on a promise to lower drug costs, in a country with among the highest prescription drug prices in the world. Right now, it takes over $2,000 out-of-pocket a month,” she said.